VRDN
$26.98-0.86 (-3.09%)
Viridian Therapeutics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor th...
Recent News
Is It Too Late To Consider Viridian Therapeutics (VRDN) After Its 82% One-Year Surge?
If you are wondering whether Viridian Therapeutics at around US$27.84 is still offering value after a strong run, the next sections will walk through what the current price might be implying. The stock has seen mixed returns, with a 2.0% decline over the past week and a 1.6% decline over the past month, yet it sits on an 81.7% return over 1 year. This stands out against its 9.3% 3 year and 61.2% 5 year returns. Recent coverage has focused on Viridian Therapeutics as investors reassess...
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit
This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating
Viridian Therapeutics, Inc. (NASDAQ:VRDN) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 27, 2026, RBC Capital lowered its price target on Viridian Therapeutics, Inc. (NASDAQ:VRDN) to $42 from $45 and maintained an Outperform rating. The analyst noted the company reported Q4 EPS and disclosed that veli’ PDUFA is scheduled for June […]